27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Between Feb 24, 2021, and March 5, 2023, 377 dyads were randomly assigned (1:1), 189 to usual treatment and 188 to intervention. 2 key findings →
Design: RCT Participants: 377 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This expert commission synthesized decades of population-level (observational) research to estimate how much dementia risk could theoretically be reduced by addressing 14 modifiable risk factors across life, from childhood education to late-life social isolation. 3 key findings →
Design: systematic-review Evidence: moderate
Full summary, score breakdown and related studies → Original source
Decreases in depression scores at 13 weeks did not differ between 111 controls and 107 participants allocated to receive sertraline (mean difference 1·17, 95% CI -0·23 to 2·58; p=0·10) or mirtazapine (0·01, -1·37 to 1·38; p=0·99), or between participants in the mirtazapine and sertraline groups (1·16, -0·25 to 2·57; p=0·11); these findings persisted to 39 weeks. 3 key findings →
Participants: 107 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Because of the exploratory nature of the analyses and the small sample sizes for subgroup analysis there is the need for caution in interpreting these data. 2 key findings →
Participants: 111 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our model could aid GPs or health service planners with the early detection of dementia. 1 key finding →
Design: case-control study Participants: 93,120 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer's disease (AD) and other proteinopathy diseases. 1 key finding →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lung macrophages play a pivotal role in pulmonary fibrosis, with monocyte-derived alveolar macrophages driving disease progression. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These data suggest that quality of life in dementia is complex, and that simple proxy substitutions of discrete measures such as cognition or function are likely to miss important factors. 5 key findings →
Participants: 101 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This qualitative evaluation of ACP in early dementia has encouragingly positive results which support the wider application of the intervention in memory services and community mental health teams. 2 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
DEMQOL and DEMQOL-Proxy show psychometric properties that are comparable with the best available dementia-specific measures of HRQL. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Six predefined service goals were set: high acceptability; high appropriate referral rate; successful engagement with people from minority ethnic groups; successful engagement with people with young onset dementia; focus on engagement with mild cases to enable early intervention; and an increase in the overall number of new cases of dementia seen. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There have, however, been few studies which have sought to investigate factors associated with carer burden and differences and similarities between countries. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The findings suggest that specific cultural attitudes towards the caregiving role have important implications for how carers can best be supported. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Gut dysbiosis, a primary factor behind various gastrointestinal disorders may also augment lipopolysaccharides, pro-inflammatory cytokines, T helper cells and monocytes causing increased intestinal and BBB permeability via microbiota-gut-brain axis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The quality of end-of-life care exists on a continuum across care settings. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The new services would cost around pound sterling 220 million extra per year nationally in England. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Further research with DEMQOL is needed to confirm these findings in an independent sample, evaluate responsiveness, investigate the feasibility of use in specific subgroups and in economic evaluation, and develop population norms. 2 key findings →
Participants: 130 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Chronic metabolic diseases, including Type 2 Diabetes, hypertension, non-alcoholic fatty liver disease (NAFLD), prostate enlargement, musculoskeletal joint friction, cardiac arrhythmias, neurodegenerative waste accumulation (Alzheimer's), and elevated intraocular hydraulic pressure (glaucoma), are frequently treated as distinct, unavoidable consequences of chronological aging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Haploinsufficiency of progranulin (resulting from mutations in the GRN gene) is a major genetic cause of frontotemporal dementia (FTD), which is characterized by profound changes in personality and behavior, progressive impairments in executive function, speech, language and/or movement, TDP-43 pathology, lysosomal dysfunction, and neuroinflammation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →